Fig. 2
From: Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy
The resveratrol nanoparticles with sustained-release and IL-13Rα2-targeting capacities (Pep-1-PEG3.5k-PCL4k@Res) were prepared to improve the in vivo resveratrol bioavailability and inhibit the growth of ATC. A Schematic illustration of synthesized Pep-1-PEG3.5k-PCL4k@Res nanoparticles. The change in tumor volume (B), body weight (C), and overall survival curve (D) of the experimental groups. Figure adapted from Le Xiong et al. [38]